Related Experiment Videos
Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial
M Pollak1, K Gallant, R Poisson
1Department of Medicine, Jewish General Hospital, Montréal, Québec, Canada.
Abstract:
Somatostatin analogues such as octreotide have been shown in experimental systems to exhibit antineoplastic activity. Further laboratory and clinical research is needed to clarify the mechanism of action of somatostatin analogues as antineoplastics, and to determine if the encouraging preclinical results will lead to novel endocrine approaches to the treatment of breast cancer.
Insights
Somatostatin analogues, like octreotide, show promise as antineoplastic agents. More research is needed to understand their mechanism and potential for treating breast cancer.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Somatostatin analogues, including octreotide, have demonstrated antineoplastic effects in preclinical studies.
- The precise mechanisms underlying these effects require further elucidation.
Purpose of the Study:
- To investigate the antineoplastic activity of somatostatin analogues.
- To explore their potential as novel endocrine therapies for breast cancer.
Main Methods:
- Review of experimental systems and laboratory research.
- Analysis of preliminary clinical data.
Main Results:
- Experimental evidence suggests antineoplastic activity of somatostatin analogues.
- Preclinical results are encouraging for further investigation.
Conclusions:
- Somatostatin analogues warrant further investigation for their role in cancer treatment.
- Potential for developing new endocrine strategies for breast cancer is indicated.